Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Ultrasound Med Biol. 2019 Oct 25;46(1):73–89. doi: 10.1016/j.ultrasmedbio.2019.09.010

Fig. 9:

Fig. 9:

In vivo feasibility in a non-human primate (NHP) model. Coronal T1-weighted, T2-weighted and susceptibility-weighted imaging (SWI) for NHPs 1 (left) and 2 (right). T1-weighted MRI confirmed blood-brain barrier opening in the thalamus (NHP 1) and dorsolateral prefrontal cortex (NHP 2), using the clinical focused ultrasound (FUS) transducer with clinically relevant parameters (MI: 0.4) and FDA-approved Definity microbubble dose (10 μl/kg). T2-weighted and SWI showed that there is no acute hemorrhage or edema after the FUS treatment. Color bar: normalized contrast enhancement. Scale bar: 1 cm.